Skip to content
by Legal Desire
20 July 2022

Latham & Watkins advises Revolution Medicines in its US$230 Public OfferingMillion

Advising firms

Deal team

16 lawyers named
LawyerFirmSeniorityPracticeOffice
Mark Roeder Lead Latham & Watkins LLP Partner corporate Bay Area
John Williams Lead Latham & Watkins LLP Partner corporate Bay Area
Zuzanna Gruca Latham & Watkins LLP Associate corporate Not stated
Taimi Jacobson Latham & Watkins LLP Associate corporate Not stated
Joshua Landis Latham & Watkins LLP Associate corporate Not stated
John Manthei Latham & Watkins LLP Partner regulatory Washington, D.C.
Elizabeth Richards Latham & Watkins LLP Partner regulatory Washington, D.C.
Heather Deixler Latham & Watkins LLP Partner regulatory Bay Area
Betty Pang Latham & Watkins LLP Counsel regulatory Bay Area
Nathan Beaton Latham & Watkins LLP Associate regulatory Washington, D.C.
Leia Gu Latham & Watkins LLP Associate regulatory Los Angeles
Grace Lee Latham & Watkins LLP Partner tax Bay Area
Derek Gumm Latham & Watkins LLP Associate tax Not stated
James Metz Latham & Watkins LLP Partner benefits and compensation Bay Area
Christopher Hazuka Latham & Watkins LLP Partner intellectual property Bay Area
Kristina Funahashi Latham & Watkins LLP Associate intellectual property San Diego

13 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.

REGISTER FREE SIGN IN

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value
USD 230m (US$230 million)
What the figure measures
Issue size
Client
Revolution Medicines, Inc.Issuer
Counterparties
Not stated